Merck KGaA, Springworks

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Merck KGaA is in advanced talks to acquire U.S. drugmaker Springworks Therapeutics, potentially impacting the healthcare sector with a sizable move in its cancer treatment pipeline. Springworks' stock ...
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck KGaA is in advanced negotiations to acquire U.S.-based Springworks Therapeutics, a move that could rank among the largest pharma deals for Merck. This potential acquisition aims to boost Merck's ...
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...